AstraZeneca Pays $2 Billion to Back Summit

$2 billion goes from AstraZeneca to Summit Therapeutics for brand-new shares, disclosed 28 September 2026, AstraZeneca said. That means the cash goes straight to Summit. AstraZeneca calls it a strategic investment. My read: backing Summit without buying it — risking money now to keep later choices open.